Literature DB >> 9033271

Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption.

A J Demetris1, N Murase, Q Ye, F H Galvao, C Richert, R Saad, S Pham, R J Duquesnoy, A Zeevi, J J Fung, T E Starzl.   

Abstract

Sequential analysis of changes that lead to chronic rejection was undertaken in an animal model of chronic rejection and obliterative arteriopathy. Brown Norway rats are pretreated with a Lewis bone marrow infusion or a Lewis orthotopic liver allograft and a short course of immunosuppression. They are challenged 100 days later with a Lewis heterotopic heart graft without immunosuppression. The heart grafts in both groups undergo a transient acute rejection, but all rats are operationally tolerant; the heart grafts are accepted and remain beating for more than 100 days. Early arterial remodeling, marked by arterial bromodeoxyuridine incorporation, occurred in both groups between 5 and 30 days during the transient acute rejection. It coincided with the presence of interstitial (but not arterial intimal) inflammation and lymphatic disruption and resulted in mild intimal thickening. Significant arterial narrowing occurred only in the bone-marrow-pretreated rats between 60 and 100 days. It was associated with T lymphocyte and macrophage inflammation of the heart graft that accumulated in the endocardium and arterial intima and adventitia near draining lymphatics. There also was loss of passenger leukocytes from the heart graft, up-regulation of cytokine mRNA and major histocompatibility class II on the endothelium, and focal disruption of lymphatics. In contrast, long-surviving heart grafts from the Lewis orthotopic liver allograft pretreated group are near normal and freedom from chronic rejection in this group was associated with persistence of donor major histocompatibility class-II-positive hematolymphoid cells, including OX62+ donor dendritic cells. This study offers insights into two different aspects of chronic rejection: 1) possible mechanisms underlying the persistent immunological injury and 2) the association between immunological injury and the development of obliterative arteriopathy. Based on the findings, it is not unreasonable to raise the testable hypothesis that direct presentation of alloantigen by donor antigen-presenting cells is required for long-term, chronic-rejection-free allograft acceptance. In addition, chronic intermittent lymphatic disruption is implicated as a possible mechanism for the association between chronic interstitial allograft inflammation and the development of obliterative arteriopathy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9033271      PMCID: PMC1858300     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  58 in total

1.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

2.  Pulmonary arteriosclerosis in long-term human heart-lung transplant recipients.

Authors:  S A Yousem; I L Paradis; J H Dauber; A Zeevi; R J Duquesnoy; R Dal Col; J Armitage; R L Hardesty; B P Griffith
Journal:  Transplantation       Date:  1989-03       Impact factor: 4.939

3.  Message amplification phenotyping (MAPPing): a technique to simultaneously measure multiple mRNAs from small numbers of cells.

Authors:  C A Brenner; A W Tam; P A Nelson; E G Engleman; N Suzuki; K E Fry; J W Larrick
Journal:  Biotechniques       Date:  1989 Nov-Dec       Impact factor: 1.993

4.  Participation of dendritic cells in vascular lesions of chronic rejection of human allografts.

Authors:  S Oguma; B Banner; T Zerbe; T Starzl; A J Demetris
Journal:  Lancet       Date:  1988-10-22       Impact factor: 79.321

Review 5.  Immunobiology of chronic renal transplant rejection.

Authors:  L C Paul
Journal:  Blood Purif       Date:  1995       Impact factor: 2.614

6.  Endocardial infiltrates in human heart transplants: a serial biopsy analysis comparing four immunosuppression protocols.

Authors:  R D Forbes; R A Rowan; M E Billingham
Journal:  Hum Pathol       Date:  1990-08       Impact factor: 3.466

7.  The intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical study.

Authors:  J F Mosnier; C Degott; P Marcellin; D Hénin; S Erlinger; J P Benhamou
Journal:  Hepatology       Date:  1993-03       Impact factor: 17.425

Review 8.  Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F344 model.

Authors:  D H Adams; M E Russell; W W Hancock; M H Sayegh; L R Wyner; M J Karnovsky
Journal:  Immunol Rev       Date:  1993-08       Impact factor: 12.988

9.  Detection of canine allograft lung rejection by pulmonary lymphoscintigraphy.

Authors:  R Ruggiero; R Fietsam; G A Thomas; J Muz; R H Farris; T A Kowal; J L Myles; L W Stephenson; F A Baciewicz
Journal:  J Thorac Cardiovasc Surg       Date:  1994-08       Impact factor: 5.209

10.  Murine liver allograft transplantation: tolerance and donor cell chimerism.

Authors:  S Qian; A J Demetris; N Murase; A S Rao; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

View more
  20 in total

1.  Migration of donor MHC class II(+) cells and increase in apoptosis: correlate to graft outcome after heart and liver transplantation.

Authors:  T Okuda; A Demetris; T Ishikawa; N Ichikawa; Y Takahashi; T Starzl; N Murase
Journal:  Transplant Proc       Date:  2001 Feb-Mar       Impact factor: 1.066

2.  Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection.

Authors:  M Terakura; Q Ye; N Ichikawa; A J Demetris; T Sakamoto; Z Liu; T E Starzl; N Murase
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

3.  Early passenger leukocyte migration and acute immune reactions in the rat recipient spleen during liver engraftment: with particular emphasis on donor major histocompatibility complex class II+ cells.

Authors:  Toyokazu Okuda; Takashi Ishikawa; Olga Azhipa; Naoya Ichikawa; Anthony J Demetris; Thomas E Starzl; Noriko Murase
Journal:  Transplantation       Date:  2002-07-15       Impact factor: 4.939

4.  Lymphatic injury and regeneration in cardiac allografts.

Authors:  Thing Rinda Soong; Arvind P Pathak; Hiroshi Asano; Karen Fox-Talbot; William M Baldwin
Journal:  Transplantation       Date:  2010-03-15       Impact factor: 4.939

5.  Abrogation of chronic rejection in a murine model of aortic allotransplantation by prior induction of donor-specific tolerance.

Authors:  V Subbotin; H Sun; A Aitouche; L A Valdivia; J J Fung; T E Starzl; A S Rao
Journal:  Transplantation       Date:  1997-09-15       Impact factor: 4.939

Review 6.  Antigen localization and migration in immunity and tolerance.

Authors:  T E Starzl; R M Zinkernagel
Journal:  N Engl J Med       Date:  1998-12-24       Impact factor: 91.245

Review 7.  Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts.

Authors:  A J Demetris; N Murase; R G Lee; P Randhawa; A Zeevi; S Pham; R Duquesnoy; J J Fung; T E Starzl
Journal:  Ann Transplant       Date:  1997       Impact factor: 1.530

8.  Pathology of Chronic Rejection: An Overview of Common Findings and Observations About Pathogenic Mechanisms and Possible Prevention.

Authors:  A J Demetris; N Murase; T E Starzl; J J Fung
Journal:  Graft (Georget Tex)       Date:  1998-05

9.  The immunolymphatic theory of chronic rejection.

Authors:  A J Demetris; N Murase; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1997-09       Impact factor: 1.066

10.  Cyclic AMP prolongs graft survival by suppressing apoptosis and inflammatory gene expression in acute cardiac allograft rejection.

Authors:  Jie-Young Lee; Jung Hwan Kim; Gibong Chae; Bong-Ki Lee; Kwon-Soo Ha; Young-Geun Kwon; Young-Myeong Kim
Journal:  Exp Mol Med       Date:  2010-01-31       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.